Fortrea Holdings (FTRE) Change in Accured Expenses (2022 - 2026)

Fortrea Holdings (FTRE) posted Change in Accured Expenses of -$43.4 million for Q1 2026, down 291.19% on a QoQ basis from $22.7 million in Q4 2025, and down 60.15% year-over-year from -$108.9 million in Q1 2025.

Fortrea Holdings (FTRE) Change in Accured Expenses (2022 - 2026) Analysis & Trends

Fortrea Holdings' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$43.4 million for Q1 2026.

  • Quarterly Change in Accured Expenses fell 60.15% year-over-year to -$43.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.8 million (down 351.28% YoY) and the FY2025 annual result came in at $6.5 million, up 30.0% from the prior year.
  • Change in Accured Expenses was -$43.4 million for Q1 2026 at Fortrea Holdings, down from $22.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $80.3 million in Q2 2023 and bottomed at -$65.1 million in Q1 2023.
  • A 5-year average of -$3.5 million and a median of -$20.7 million in 2024 frame the typical range for Change in Accured Expenses.
  • Annual changes were most pronounced in 2024 — Change in Accured Expenses slumped 96.26% — and 2025, when it surged 746.67%.
  • Fortrea Holdings' Change in Accured Expenses stood at -$22.7 million in 2022, then surged by 253.3% to $34.8 million in 2023, then jumped by 39.94% to $48.7 million in 2024, then slumped by 53.39% to $22.7 million in 2025, then slumped by 291.19% to -$43.4 million in 2026.
  • Business Quant data shows FTRE's Change in Accured Expenses at -$43.4 million in Q1 2026, $22.7 million in Q4 2025, and -$14.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Oculis Holding AG 66,981.90 Bn 66,981.62 Bn - 1.13 Mn
2 Nanobiotix 1,930.48 Bn 1,930.42 Bn - -
3 Akari Therapeutics 1,071.19 Bn 1,071.19 Bn - 931,000.00
4 BeOne Medicines 468.55 Bn 463.76 Bn 1.35 Bn -16.82 Mn
5 Vertex Pharmaceuticals 123.04 Bn 115.79 Bn 2.59 Bn 23.10 Mn
6 Regeneron Pharmaceuticals 70.31 Bn 61.56 Bn 3.31 Bn 107.70 Mn
7 Belite Bio 63.40 Bn 63.40 Bn - -
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.67 Bn 34.66 Bn 959.66 Mn -176.03 Mn
10 Fortrea Holdings 1.84 Bn 1.69 Bn 123.60 Mn -43.40 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -43.40 Mn
Mar 31, 2026 -43.40 Mn
Dec 31, 2025 22.70 Mn
Dec 31, 2025 22.70 Mn
Sep 30, 2025 -14.50 Mn
Sep 30, 2025 -14.50 Mn
Jun 30, 2025 25.40 Mn
Jun 30, 2025 25.40 Mn
Mar 31, 2025 -27.10 Mn
Mar 31, 2025 -27.10 Mn
Dec 31, 2024 48.70 Mn
Dec 31, 2024 48.70 Mn
Sep 30, 2024 -20.70 Mn
Sep 30, 2024 -20.70 Mn
Jun 30, 2024 3.00 Mn
Jun 30, 2024 3.00 Mn
Mar 31, 2024 -26.00 Mn
Mar 31, 2024 -26.00 Mn
Dec 31, 2023 34.80 Mn
Dec 31, 2023 34.80 Mn